To evaluate the prognostic value of 3- and 12-month on-treatment serum neurofilament light chain (sNfL) levels for future disease activity in people with relapsing multiple sclerosis (pwRMS).
No takes yet. Share an insight, caveat, or question.
Leist et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: